Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Mallinckrodt
Medtronic
Johnson and Johnson
McKinsey

Last Updated: May 27, 2022

Investigational Drug Information for TD-9855


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for TD-9855?

TD-9855 is an investigational drug.

There have been 9 clinical trials for TD-9855. The most recent clinical trial was a Phase 3 trial, which was initiated on January 24th 2019.

The most common disease conditions in clinical trials are Hypotension, Pure Autonomic Failure, and Hypotension, Orthostatic. The leading clinical trial sponsors are Theravance Biopharma, Theravance Biopharma R & D, Inc., and [disabled in preview].

There are eighteen US patents protecting this investigational drug and one hundred and seventeen international patents.

Recent Clinical Trials for TD-9855
TitleSponsorPhase
Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855Theravance BiopharmaPhase 1
Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureTheravance BiopharmaPhase 3
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureTheravance BiopharmaPhase 3

See all TD-9855 clinical trials

Clinical Trial Summary for TD-9855

Top disease conditions for TD-9855
Top clinical trial sponsors for TD-9855

See all TD-9855 clinical trials

US Patents for TD-9855

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
TD-9855 See Plans and Pricing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) See Plans and Pricing
TD-9855 See Plans and Pricing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) See Plans and Pricing
TD-9855 See Plans and Pricing Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) See Plans and Pricing
TD-9855 See Plans and Pricing Methods for treating neurogenic orthostatic hypotension THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for TD-9855

Drugname Country Document Number Estimated Expiration Related US Patent
TD-9855 Argentina AR074128 2028-11-14 See Plans and Pricing
TD-9855 Argentina AR074350 2028-11-14 See Plans and Pricing
TD-9855 Argentina AR114965 2028-11-14 See Plans and Pricing
TD-9855 Australia AU2009313948 2028-11-14 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Mallinckrodt
Medtronic
Johnson and Johnson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.